News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,981 Results
Type
Article (40022)
Company Profile (250)
Press Release (664708)
Multimedia
Podcasts (60)
Webinars (14)
Section
Business (204282)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81140)
Employer Resources (172)
FDA (16252)
Job Trends (14889)
News (345511)
Policy (32607)
Tag
Academia (2556)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (109)
Alzheimer's disease (1445)
Antibody-drug conjugate (ADC) (151)
Approvals (16248)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (123)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (366)
Cancer (2876)
Cardiovascular disease (213)
Career advice (1682)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (500)
Cervical cancer (22)
Clinical research (66868)
Collaboration (1017)
Company closure (3)
Compensation (690)
Complete response letters (23)
COVID-19 (2624)
CRISPR (57)
C-suite (330)
Cystic fibrosis (113)
Data (3013)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (346)
Diagnostics (6426)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (130)
Earnings (87469)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113750)
Executive appointments (846)
FDA (17912)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (933)
Gene editing (131)
Generative AI (22)
Gene therapy (375)
GLP-1 (783)
Government (4504)
Grass and pollen (4)
Guidances (182)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (9)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (53)
Layoffs (494)
Leadership (19)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (402)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (390)
MASH (91)
Medical device (13465)
Medtech (13470)
Mergers & acquisitions (19584)
Metabolic disorders (850)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (116)
Neuropsychiatric disorders (32)
Neuroscience (2125)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (48)
Obesity (428)
Opinion (217)
Ovarian cancer (101)
Pain (107)
Pancreatic cancer (121)
Parkinson's disease (186)
Partnered (22)
Patents (302)
Patient recruitment (167)
Peanut (50)
People (57695)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20832)
Phase II (29453)
Phase III (21921)
Pipeline (1644)
Policy (201)
Postmarket research (2563)
Preclinical (8872)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (460)
Real estate (5917)
Recruiting (66)
Regulatory (22643)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3588)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (58)
The Weekly (38)
Vaccines (779)
Venture capital (54)
Weight loss (257)
Women's health (47)
Worklife (16)
Date
Today (75)
Last 7 days (341)
Last 30 days (1830)
Last 365 days (31166)
2025 (16878)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38217)
Australia (6233)
California (7454)
Canada (2364)
China (672)
Colorado (320)
Connecticut (319)
Delaware (192)
Europe (82120)
Florida (1121)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (639)
India (27)
Indiana (361)
Iowa (17)
Japan (229)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1027)
Massachusetts (5538)
Michigan (246)
Minnesota (452)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2081)
New Mexico (28)
New York (2089)
North Carolina (1082)
North Dakota (8)
Northern California (3282)
Ohio (237)
Oklahoma (16)
Oregon (34)
Pennsylvania (1615)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2792)
Tennessee (126)
Texas (1127)
United States (27626)
Utah (220)
Virginia (187)
Washington D.C. (72)
Washington State (634)
West Virginia (4)
Wisconsin (66)
704,981 Results for "cohbar inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
CohBar Reports Second Quarter 2023 Financial Results
CohBar, Inc. reported its financial results and highlights for the second quarter ended June 30, 2023.
August 14, 2023
·
7 min read
Business
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0
Morphogenesis, Inc. and CohBar, Inc. (CWBR) (“CohBar”), today announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.
June 5, 2023
·
13 min read
Biotech Bay
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Morphogenesis, Inc. (“Morphogenesis”) and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.
May 30, 2023
·
10 min read
Business
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - May 30, 2023
Morphogenesis, Inc. and CohBar, Inc. today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 30, 2023
·
10 min read
Business
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
CohBar, Inc. and Morphogenesis, Inc. today announced that they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
May 23, 2023
·
14 min read
Business
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced MCC and Cutaneous Squamous Cell Carcinoma (cSCC)
Morphogenesis, Inc. and CohBar, Inc., announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.
June 5, 2023
·
12 min read
Deals
CohBar Announces Reverse Stock Split
CohBar, Inc. today announced that its Board of Directors (the “Board”) has approved a 1-for-30 reverse stock split of the company’s common stock.
September 22, 2022
·
6 min read
Business
CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
CohBar, Inc. reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress.
November 8, 2022
·
9 min read
Biotech Bay
CohBar to Participate at Upcoming Conferences in June 2022
CohBar, Inc. announced that its Chief Executive Officer, Dr. Joseph Sarret, will participate at two upcoming conferences.
June 7, 2022
·
2 min read
Business
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
CohBar, Inc. announced that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022.
October 26, 2022
·
2 min read
1 of 70,499
Next
